143656-79-5

Upstream product

• 143656-80-8 benzyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 799767-82-1 benzyl 3-bromo-4-hydroxypyrrolidine-1-carboxylate 
• 31865-25-5 benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 203503-07-5 3-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-4-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 
• 1247884-17-8 benzyl 3-hydroxy-4-(picolinamido)pyrrolidine-1-carboxylate 
• 1440955-15-6 benzyl 3-acetamido-4-oxopyrrolidine-1-carboxylate 
• 1440955-16-7 2-methyl-4,6-dihydro-pyrrolo[3,4-d]oxazole-5-carboxylic acid benzyl ester 
• 1246893-01-5 benzyl 2-(pyridin-2-yl)-4H-pyrrolo[3,4-d]oxazole-5(6H)-carboxylate 
• 1246893-00-4 benzyl 3-oxo-4-(picolinamido)pyrrolidine-1-carboxylate 
• 1440955-14-5 benzyl 3-acetamido-4-hydroxypyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors

Amino ketone warheads were explored as alternatives to the nitrile group of a potent and selective cathepsin K inhibitor. The resulting compounds were potent and selective inhibitors of cathepsin K and these nitrile replacements had a significant effect o